A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.

Roy, Tina; Barrows, Elizabeth; Mainor, Candace; Collins, Julie; Lynce, Filipa; Isaacs, Claudine; Pohlmann, Paula R

Roy, Tina; Barrows, Elizabeth; Mainor, Candace; Collins, Julie; Lynce, Filipa; Isaacs, Claudine; Pohlmann, Paula R.

Affiliation

Roy T; Department of Internal Medicine, Georgetown University Medical Center, 3800 Reservoir Road, Washington, DC, 20007, USA.
Barrows E; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, Washington, DC, 20007, USA.
Mainor C; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, Washington, DC, 20007, USA.
Collins J; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, Washington, DC, 20007, USA.
Lynce F; AZ, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.
Isaacs C; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, Washington, DC, 20007, USA.
Pohlmann PR; Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

Contemp Clin Trials Commun ; 33: 101110, 2023 Jun.

Article de En | MEDLINE | ID: mdl-37026029

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Contemp Clin Trials Commun Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google